archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • THROMBOTROL®-VF
    VF using the Mix2Vial Mix2Vial THROMBOTROL VF is a freeze dried preparation of human antithrombin III THROMBOTROL VF contains antithrombin III which is a protein normally present in the blood that prevents the formation of blood clots THROMBOTROL VF may be administered as a preventative measure prior to surgery or during pregnancy and childbirth in patients with an inherited deficiency of antithrombin III Such patients may be at risk of spontaneous thrombosis blood clots or pulmonary embolism blood clot which stops blood circulating through the lungs The risk of these conditions increases with age and in association with surgery pregnancy and childbirth THROMBOTROL VF increases antithrombin III levels in the blood and thereby decreases the risk of blood clots THROMBOTROL VF is supplied as a freeze dried powder which is dissolved with Water for Injections and then injected into a vein Each vial of THROMBOTROL VF is packaged with one vial of Water for Injections and a plastic Mix2Vial filter transfer set that is used to transfer the Water for Injections into the THROMBOTROL VF vial THROMBOTROL VF is available only with a doctor s prescription Data sheet The data sheet contains information to ensure the safe and effective use

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562765747/Web_Product_C/1196562733109/ProductDetail.htm (2014-01-05)
    Open archived version from archive


  • BIOSTATE®
    Human coagulation factor VIII Freeze dried For further information visit the Centre for Transfusion Medicine at HSA Health Sciences Authority website For information on how to prepare BIOSTATE using the Mix2Vial Mix2Vial BIOSTATE is a freeze dried preparation containing human coagulation factor VIII a protein which is essential for normal blood clotting BIOSTATE is used to replace factor VIII in people with haemophilia A a bleeding disorder in which there are reduced levels of factor VIII People with low levels of factor VIII may have difficulty forming blood clots and these clots may take longer to form Sometimes people with low levels of factor VIII may bleed spontaneously into their joints or muscles BIOSTATE is supplied as a freeze dried powder which is dissolved with Water for Injections and then injected into a vein Each vial of BIOSTATE is packaged with one vial of Water for Injections and a plastic Mix2Vial filter transfer set that is used to transfer the Water for Injections into the BIOSTATE vial Product Information Product Information contains information to ensure the safe and effective use of a medicine This document is approved by the national health regulator in Singapore and made available by CSL for

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562765747/Web_Product_C/1196562733490/ProductDetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Limited today announced Full Year Results for 2010/11.
    11 when compared to the prior comparable period This result included an unfavourable foreign exchange impact of 116 million On a constant currency 1 basis operational net profit after tax grew 14 after excluding a one off contribution from the sale of pandemic influenza vaccine H1N1 in the prior period Download this release CSL Full Year results announcement for 20010 11 0 1 Mb Additional resources The Webcast Analyst presentation

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1255927066660/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Recombinant Technologies
    Limited ASX CSL subsidiary CSL Behring today issued a press release regarding advances that it is making in developing innovative new technologies to meet the unmet therapeutic needs of patients with haemophilia A and B This will be the topic of an oral presentation at an international medical congress on 22 May 2011 A copy of this press release is available on the CSL Behring website and is included in

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1255926420967/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Limited today announced its first half result for period ended 31 December 2010.
    Businesses Our Products Research and Development Business Development Investors Corporate Responsibility Careers Newsroom Contact CSL Home Archived ASX Releases Half year results announcement for 2010 11 Half year results announcement for 2010 11 Melbourne Australia 16 02 2011 CSL Limited today announced its first half result for period ended 31 December 2010 Download this release CSL Half Year Results Announcement for 2010 11 0 1 Mb Additional resources The Webcast

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1255925859621/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Appoints New Director
    State Global Asset Management a position that she has held since July 2007 In this capacity she is a director of the Anglian Water Group UK and Electricity North West UK Prior to her position with Colonial First State Global Asset Management she was the Chief Executive Officer of the GasNet Australia Group from October 2001 until December 2006 Ms O Reilly holds a Bachelor of Business and qualified as

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1255925861380/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Recording of June 9, 2009 Analyst Briefing
    2009 Analyst Briefing with CSL Managing Director and Chief Executive Officer Dr Brian McNamee This was recorded on June 9th 2009 following the announcement that CSL and Talecris Biotherapeutics have agreed to terminate the merger agreement CSL and Talecris Biotherapeutics Agree to Terminate Merger Agreement 0 1Mb Listen Now This recording is approximately 30 minutes long and can be listened to stopped and restarted using the controls below Media Contacts

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1187378853231/news/1242704012355/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Recording of Analyst Briefing
    of Analyst Briefing Melbourne Victoria 28 05 2009 Analyst Briefing with CSL Managing Director and Chief Executive Officer Dr Brian McNamee This was recorded on May 28th 2009 following CSL s response to the FTC announcement regarding CSL Limited s acquisition of Talecris CSL Limited responds to FTC announcement Listen Now This recording is approximately one hour long and can be listened to stopped and restarted using the controls below

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1187378853231/news/1242703935711/prdetail.htm (2014-01-05)
    Open archived version from archive